Inspire Investing LLC Sells 104,529 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Inspire Investing LLC reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 66.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 53,479 shares of the biotechnology company’s stock after selling 104,529 shares during the quarter. Inspire Investing LLC’s holdings in BioCryst Pharmaceuticals were worth $402,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after acquiring an additional 127,708 shares during the period. Fisher Asset Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 16.9% during the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after purchasing an additional 481,359 shares during the period. Two Sigma Advisers LP grew its holdings in shares of BioCryst Pharmaceuticals by 13.6% in the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after purchasing an additional 261,500 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in shares of BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after buying an additional 84,102 shares during the period. Finally, FMR LLC raised its holdings in BioCryst Pharmaceuticals by 2.4% during the 3rd quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock valued at $15,112,000 after buying an additional 46,110 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $7.64 on Friday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -12.52 and a beta of 1.76. The stock’s 50 day simple moving average is $7.57 and its two-hundred day simple moving average is $7.66.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. The company’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays boosted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Evercore ISI increased their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.17.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.